We recently demonstrated that axonal transport of adeno-associated virus (AAV) is serotype-dependent. Thus, AAV serotype 2 (AAV2) is anterogradely transported (e.g., from cell bodies to nerve terminals) in both rat and non-human primate (NHP) brain. In contrast, AAV serotype 6 (AAV6) is retrogradely transported from terminals to neuronal cell bodies in the rat brain. However, the directionality of axonal transport of AAV6 in the NHP brain has not been determined. In this study, two Cynomolgus macaques received an infusion of AAV6 harboring green fluorescent protein (GFP) into the striatum (caudate and putamen) by magnetic resonance (MR)-guided convection-enhanced delivery. One month after infusion, immunohistochemical staining of brain sections revealed a striatal GFP expression that corresponded well with MR signal observed during gene delivery. As shown previously in rats, GFP expression was detected throughout the prefrontal, frontal and parietal cortex, as well as the substantia nigra pars compacta and thalamus, indicating retrograde transport of the vector in NHP. AAV6-GFP preferentially transduced neurons, although a few astrocytes were also transduced. Transduction of non-neuronal cells in the brain was associated with the upregulation of the major histocompatibility complex-II and lymphocytic infiltration as previously observed with AAV1 and AAV9. This contrasts with highly specific neuronal transduction in the rat brain. Retrograde axonal transport of AAV6 from a single striatal infusion permits efficient transduction of cortical neurons in significant tissue volumes that otherwise would be difficult to achieve.
INTRODUCTION
Axonal transport of intact virions is a critical issue when designing a gene therapy for a particular central nervous system pathology, as it defines the brain areas that will be transduced and may predict off-target effects. Consequently, defining the directionality of axonal transport of vectors, such as adeno-associated virus (AAV), is essential. Retrograde transport requires uptake of vector by axonal projections within the infusion site and transport to the distally located soma where it transduces the host cell nucleus. In contrast, anterograde transport involves entry of vector into cell bodies at the infusion site. A subset of intact virions travels through axons to these neuronal terminals, to be released at the axon terminal, and become available to transduce neighboring cells. 1 We have consistently found that AAV serotype 2 (AAV2) is transported anterogradely in rat and non-human primate (NHP) brain. [2] [3] [4] For instance, when infused into the striatum, AAV2 transduces regions to which striatal neurons project like globus pallidus, substantia nigra pars reticulata and subthalamic nucleus. 2 When delivered to the thalamus, AAV2 particles travel along thalamic axons to several cortical areas. 3 More recently, to elucidate the AAV serotype 6 (AAV6) vector behavior, we compared AAV6 with AAV2 in the rat brain. 5 Parenchymal infusion of AAV6 harboring green fluorescent protein (GFP) into either the striatum or the thalamus revealed GFP staining in cell bodies of regions projecting to the infusion target nuclei, whereas, as expected, GFP expression in rats that received AAV2 was mainly found in areas to which either the striatum or the thalamus project. Although they exhibited a different directionality in axonal transport in rat brain, both AAV6 and AAV2 demonstrated a strongly neuronal tropism.
In our experience, however, it can be risky to extrapolate data obtained in rodents to the primate brain. 6 Thus, in the present study we investigated whether AAV6 is also transported retrogradely in the primate brain. We infused AAV6 into NHP brain parenchyma by convection-enhanced delivery, a pressurized parenchymal infusion technique that allows therapeutic agents to be distributed throughout large volumes of brain. 7, 8 Our group has optimized this delivery technique during the past decade primarily by coinfusing the AAV vector with a magnetic resonance imaging (MRI) contrast agent that allows real-time visualization of the infusion. 9, 10 Pathologies such as lysosomal storage diseases, Parkinson's disease, Alzheimer disease and Huntington's disease (HD) could benefit from an AAV6-based gene therapy.
RESULTS

AAV6 distribution
We bilaterally infused AAV6-GFP into the striatum (caudate nucleus and putamen) of two Cynomolgus macaques by convection-enhanced delivery to ensure optimal distribution of the infusate. [7] [8] [9] [10] To visualize the infusion in real time, AAV vector was coinfused with chelated gadolinium (Prohance, Bracco), an MR-compatible tracer. MRI contrast showed good coverage of both putamen (two to three injection sites per hemisphere) and caudate nucleus in both animals ( Figure 1 ). No leakage outside the target nuclei was observed; however, some perivascular draining of the infusate through striatal large blood vessels was seen in MRI during the infusion (Figure 1 , black arrow). Slight reflux was observed after removing the cannulae. There were no adverse effects related to the infusion procedure or the vector postoperatively.
Three to four weeks after infusion, animals were euthanized, brains harvested and histologically analyzed. Immunohistochemical staining against GFP revealed well-contained expression within both the caudate nucleus and putamen for both animals ( Figures  1 and 2 ). Stained areas within these structures corresponded well with the MRI signal during infusion. GFP-transduced neurons and fibers were particularly abundant around blood vessels at the infusion sites. 11 Further immunohistochemical examination of GFP expression in the brain demonstrated GFP in cell bodies of the prefrontal, frontal and parietal cortex, as well as the substantia nigra pars compacta neurons and thalamus, indicating retrograde transport of the vector (Figure 2 ), as these brain areas project to the striatum. The lateral globus pallidus also contained GFPexpressing neuronal bodies, even though it does not have direct axons projecting to either the caudate nucleus or the putamen. We believe that this may be an example of non-axonal transport via perivascular spread. 11 Moreover, some GFP-immunostained fibers could be found in the substantia nigra reticulata (data not shown). This staining represents merely cytoplasmic distribution of GFP protein within a transduced neuron. 12 It is rather the presence of transduced cell bodies in non-injected areas of the brain that is indicative of potential axonal transport of the vector. In all these areas, the morphology of the cells positively stained for GFP suggested that they were mainly, but not exclusively, neurons.
AAV6 tropism in NHP brain
To establish the cellular tropism of AAV6-GFP vector after parenchymal infusion in NHP, we immunostained brain sections for the transgene and cell-specific markers such as NeuN for neurons and glial fibrillary acid protein (GFAP) for astrocytes. Double immunofluorescent staining revealed that the majority of the GFP-expressing cells were positive for NeuN neuronal marker ( Figure 3 ). GFP/NeuN-positive cells were present both in the infusion nuclei (i.e., caudate nucleus and putamen; Figure 3a ) as well as in distal structures, such as the prefrontal cortex (Figure 3b ), that project to the infusion areas, supporting the retrograde transport of the AAV6-GFP vector.
On the other hand, we also occasionally found GFP-stained cells that also expressed GFAP astrocytic marker ( Figure 3c ). The few GFP/GFAP cells were located near the infusion site. Taken together with the large number of GFP-positive neurons (NeuNpositive cells) found, this finding supports the mainly neuronal tropism of AAV6 when infused in the NHP brain. Our previous demonstration that transduction of non-neuronal cells with AAV1 5 or AAV9 11 encoding a foreign protein like GFP engages the adaptive immune system raised concerns that even the modest astrocytic transduction observed with AAV6 in NHP brain might nevertheless trigger immune activation. As shown in Figure 4 , AAV6-mediated GFP expression in NHP putamen was associated with significant upregulation of the major histocompatibility complex-II (MHC-II)-expressing cells (Figure 4 bottom), something we have never observed with AAV2-GFP (Figure 4 top). However, the degree of MHC-II upregulation at 21 days after vector infusion was much less than that seen with AAV9-GFP at the same dose and postinfusion period consistent with the more robust astrocytic transduction seen with AAV9 previously described in rodents. 11 
DISCUSSION
In the present study, we report that AAV6 vector is transported retrogradely in the NHP brain, confirming findings in rodents. 13 Retrograde transport of intact virions consists of uptake of virions by axonal projections within the site of delivery and their transport to the distally located soma that is consequently transduced resulting in the presence of the transgenic protein throughout the neuron. Our data clearly show retrograde transport demonstrated by the presence of the transgenic protein in neuronal bodies of regions that send axonal projections to the striatum (i.e., prefrontal cortex, substantia nigra pars compacta, thalamus).
However, finding GFP-positive cell bodies in the globus pallidus was unexpected because this deep brain nucleus does not have axonal terminals in either the caudate nucleus or the striatum. During the infusion into the putamen, we observed that some of the AAV6-GFP infusate traveled rapidly through the perivascular space of some large blood vessels within the base of this structure. Probably this pathway facilitated the transport of the vector to adjacent structures such as the globus pallidus, resulting in the 11 Fibers containing GFP could be seen in the substantia nigra pars reticulata. This fact would fit better with an anterograde rather than retrograde transport of the vector. However, no GFP-positive cell bodies could be seen in the substantia nigra pars reticulata, a phenomenon that would rather describe an anterograde axonal transport. As this structure receives axons from the striatum, those fibers probably belong to those striatal neurons transduced by AAV6-GFP at the infusion sites. Transgenic proteins are often present at high levels in the cytoplasm of transduced neurons and, therefore, neuronal fibers in distally innervated brain nuclei can be positive for the expressed protein. This phenomenon has previously been described 12, 13 and it should not be confused with anterograde transport of the vector, as there were no GFP-positive cell bodies in the substantia nigra reticulata.
As already largely demonstrated for AAV2, AAV6 mainly transduces neurons when infused into the brain parenchyma of either rodents or NHP. In the two macaques of this study, few astrocytes expressed GFP and they were located close to the infusion sites. AAV6's neuronal tropism is a very interesting feature, as it has been recently described that the expression of foreign transgenic proteins by glia after AAV infusion can result in a cell-mediated immune response, given that these cells are antigen-presenting cells in the brain.
14 AAV serotype 9 (AAV9) efficiently transduces both neurons and astrocytes. Thus, striatal infusion of AAV9 encoding non-self genes in the rat brain triggered an immune response that resulted in neuronal death within the transduced regions. Even though AAV6 in NHP brain still shows a strong preference for neurons as it does in rats, we wondered whether even the modest non-neuronal transduction seen in NHP was sufficient to trigger an immune response. To our surprise, AAV6 induced a brisk upregulation of MHC-II just as we saw with AAV1-hrGFP 6 and AAV9-GFP. 14 As we have repeatedly emphasized, this response is driven by expression of GFP, a non-self, protein and is not directed at AAV6 itself. With that proviso, it appears that AAV6 evinces the same retrograde axonal transport properties in NHP as it does in rats. 5 Altogether, AAV6 raises as an adequate viral vector for neurological diseases. Although its ability to be retrogradely transported through axons may be of great value for some of AAV6 retrograde transport in NHP brain W San Sebastian et al them, AAV6 is not recommended when aiming for local expression of the transgene. For instance, if AAV6 carrying a therapeutic transgene for Parkinson's disease is delivered into the striatum, the transgene would also be expressed in the cortex when the most affected area in this pathology is the substantia nigra pars compacta. Accordingly, among other pathologies, HD would be a disorder that could particularly benefit from an AAV6-based gene therapy. HD is an autosomal-dominant neurodegenerative disease caused by a mutation in exon 1 of the gene encoding Huntingtin (Htt) protein 15 that confers a gain of functional toxicity. 16 HD neuropathology is characterized by the atrophy of primarily the striatum, with massive degeneration of the striatal medium spiny neurons and cortex, although other brain regions (e.g., thalamus, hippocampus and white matter) are also affected. Accordingly, most of the preclinical therapies being investigated aim to reduce the presence of mutant Htt protein in the striatum and the cortex. 17, 18 However, delivering a therapeutic agent to these regions remains a challenge, in particular to an area as extensive as the cortex. Thus, based on its ability to be retrogradely transported, AAV6 emerges as an appropriate candidate to achieve a wide distribution throughout the cortex. Our results in both rat and NHP demonstrate that infusion of AAV6 in the striatum yields transduction of striatal medium spiny neurons as well as transduction of cortical regions where corticostriatal projections originate, 19, 20 and even regions secondarily affected in HD as thalamus. In addition, real-time monitoring of the infusion will allow us to ensure optimal coverage of the atrophic striatum in HD patients.
MATERIALS AND METHODS Animals
Two adult female Cynomolgus macaques (Macaca fascicularis, B3 kg, 5 years old) were included in this study. Experiments were performed according to National Institutes of Health guidelines and to protocols approved by the Institutional Animal Care and Use Committee at University of California San Francisco.
Vector production GFP cDNA was cloned into an AAV6 shuttle plasmid, and a recombinant AAV6-containing GFP under the control of the chicken b-actin promoter was manufactured by the AAV Clinical Vector Core at Children's Hospital of Philadelphia as described previously. 21, 22 AAV6-GFP was purified from cell extracts by CsCl centrifugation and was concentrated to approximately 2.3 Â 10 13 vector genomes per ml.
Surgical procedure and vector infusion NHP underwent stereotactic placement of skull-mounted, MR-compatible, temporary plastic plugs. NHP was placed supine in an MRI-compatible stereotactic frame. After craniectomy, the cannula trajectory guide devices were secured to the skull over both hemispheres. After placement of the plugs, the intubated animal was moved into the MRI suite and placed on inhaled isoflurane (1-3%). With the animal in the MR magnet, guides were filled with chelated gadolinium (MR-visible tracer; Prohance, Singem, Germany) prepared under sterile conditions and used to localize the plugs in the MR images to calculate the trajectory to the target structures inside the brain. Then, the NHP was moved into the bore and high-resolution anatomical MR scan was acquired for target identification and surgical planning. Once the target was selected, a custom-designed, ceramic, fused silica reflux-resistant cannula with a 3-mm stepped tip 9, 23 was used for the infusion. The cannula was attached to a 1-ml syringe mounted onto an MRI-compatible infusion pump (Harvard Bioscience, Holliston, MA, USA). AAV6-GFP vector delivery was performed by CED. Briefly, infusion was initiated at 1 ml min À 1 and, after visualizing fluid flow from the cannula tip when held at the height of the NHP head, the cannula was inserted through the plug and into the brain. When the depth stop encountered the top of the guide stem, it was secured with a locking screw. After visualization of gadolinium infusion at the cannula tip, the infusion rate was ramped up from an initial 1 ml min À 1 to a maximum of 3 ml min À 1 . Each NHP first received an infusion at 2 locations (pre-and postcommissural) in each putamen (bilateral) and then in one (left) or both caudate nuclei. The total infusion volume per hemisphere was 80 and 90 ml on the left or right side, respectively, for one animal (NHP1, anterior putamen: 30 ml per left; 60 ml per right; posterior putamen: 9 ml per left1, 10 ml per left, 29 ml per right; caudate nucleus: 30 ml per left) and 135 ml for the other (NHP2 anterior putamen: 40 ml per side; posterior putamen: 55 ml per side; caudate nucleus: 40 ml per side). Once the infusion ended, guide devices were removed from the skull, and animals were taken back to their home cages and monitored during recovery from anesthesia.
Tissue processing
Each NHP was perfused transcardially with phosphate-buffered saline (PBS) and PBS/4% paraformaldehyde 3-4 weeks after the infusion session. Sectioning and immunostaining of brain tissue was performed as described previously. 24 Briefly, brains were harvested, sliced in 6-mm coronal sections in a brain matrix, postfixed in PBS/4% paraformaldehyde and cryoprotected in 30% (w v À 1 ) sucrose. A sliding microtome was used to cut 40-mm serial sections for histological processing. For immunohistochemistry, sections were first washed in PBS followed by treatment with 1% H 2 O 2 /30% ethanol in PBS to block endogenous peroxidase. Sections were then incubated in Sniper blocking solution (Biocare Medical, Concord, CA, USA) followed by incubation with corresponding GFP primary antibody (rabbit anti-GFP, 1:1000, G10362; Molecular Probes, Eugene, OR, USA) in Da Vinci Green diluent (Biocare Medical) overnight at 4 1C. Sections were rinsed in PBS/0.1% Tween-20 (PBST) and incubated in Rabbit Mach 2 HRP Polymer (Biocare Medical) for 1 h, followed by several washes and colorimetric development with 3,3 0 -diaminobenzidine. Immunostained sections were mounted on slides and sealed with a toluene-based mounting media (Shandon-Mount; Thermo Scientific, Kalamazoo, MI, USA). GFP-stained sections of one of the animals were counterstained with Nissl. Double immunofluorescence staining was performed to characterize GFP-expressing cells. Sections containing striatal infusion site were washed in PBST and incubated overnight at ambient temperature with a mixture of GFP primary antibody (rabbit anti-GFP, 1:1000, G10362; Molecular Probes) and specific antibodies against either neurons (anti-NeuN, mouse monoclonal, 1:500, MAB377; Millipore, Temecula, CA, USA) or astrocytes (mouse GFAP, 1:500, MAB360; Millipore). Next day, sections were rinsed in PBST and incubated for 2 h in a cocktail of the corresponding secondary antibodies conjugated to either Alexa 488 or 555 fluorophores (Molecular Probes). To detect MHC-II and CD8, sections were stained as described above with anti-MHC-II (monoclonal mouse anti-MHC-II, 1:300, M3887-30; US Biologicals, Salem, MA, USA) or with anti-CD8 (monoclonal mouse antiCD8a, 1:100, MCA4609T; AbD Serotec, Raleigh, NC, USA) as described.
